ReviewOncotarget2017
Genomic alterations of ERBB receptors in cancer: clinical implications.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 131 citations in OpenAlex.
- Rewiring oncogenic signalling to precision ablation of metastatic cancer.Nature biomedical engineering · 2026Article
- Incorporation of network pharmacology, molecular docking, survival, density functional theory, and experimental studies to explore the potential key targets of formononetin by TERT-mediated anti-cancer effects in MCF-7 breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncology research · 2026Review
- Translating genomic insights into therapy: an NGS-based mutation profiling study in breast cancer.Medical oncology (Northwood, London, England) · 2025Article
- Article
- Genes related to neural tube defects and glioblastoma.Scientific reports · 2025Article
- Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.NPJ precision oncology · 2024Article
- HER2-targeted therapies beyond breast cancer - an update.Nature reviews. Clinical oncology · 2024Review
- Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.European journal of clinical pharmacology · 2024Review
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.Targeted oncology · 2024Article
- Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.Cellular & molecular immunology · 2024Review
- Dysregulated Expression Patterns of Circular RNAs in Cancer: Uncovering Molecular Mechanisms and Biomarker Potential.Biomolecules · 2024Review
- Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium.Virchows Archiv : an international journal of pathology · 2024Review
- Review
- MetastaticBMJ case reports · 2023Article
- miRNA analysis reveals novel dysregulated pathways in amyotrophic lateral sclerosis.Human molecular genetics · 2023Article
- Regulation of ErbB Receptors by the CaBiomedicines · 2023Review
- Cell-specific cargo delivery using synthetic bacterial spores.Cell reports · 2023Article
- A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification.Frontiers in oncology · 2023Article
- Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.Frontiers in molecular biosciences · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The ERBB family of receptor tyrosine kinases has been implicated in carcinogenesis for over three decades with rigorous attention to EGFR and HER2. ERBB receptors, consisting of EGFR, HER2, HER3, and HER4 are part of a complicated signaling network that activates downstream signaling pathways including PI3K/AKT, Ras/Raf/MAPK, JAK/STAT and PKC. It is well established that EGFR is amplified and/or mutated in gliomas and non-small-cell lung carcinoma while HER2 is amplified and/or over-expressed in breast, gastric, ovarian, non-small cell lung carcinoma, and several other tumor types. With the advent of next generation sequencing and large scale efforts to explore the entire spectrum of genomic alterations involved in human cancer progression, it is now appreciated that somatic ERBB receptor mutations occur at relatively low frequencies across multiple tumor types. Some of these mutations may represent oncogenic driver events; clinical studies are underway to determine whether tumors harboring these alterations respond to small molecule EGFR/HER2 inhibitors. Recent evidence suggests that some somatic ERBB receptor mutations render resistance to FDA-approved EGFR and HER2 inhibitors. In this review, we focus on the landscape of genomic alterations of EGFR, HER2, HER3 and HER4 in cancer and the clinical implications for patients harboring these alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.